Related Experiment Video
Updated: Aug 16, 2026
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
The influence of HER2 genotypes as molecular markers in ovarian cancer outcome
Daniela Pinto1, Deolinda Pereira, Catarina Portela
1Pathology and Molecular Oncology Unit, Portuguese Institute of Oncology, Porto, Portugal. patpriv@ipoporto.min-saude.pt
Abstract:
A relevant clinical problem in the treatment of ovarian cancer (OC) is the development of resistance to chemotherapy, frequently due to genetic variations in enzymes and receptors. Changes in the HER2 receptor have been associated with breast and ovarian cancers. The role of a polymorphism in the HER2 gene in the clinical outcome of OC patients was investigated in this study. We characterized DNA samples from 111 patients with OC treated with cisplatin and paclitaxel, using PCR-RFLP. Our results indicate that patients carrying the valine homozygotic genotype present a lower overall survival mean, suggesting a role for this polymorphism in the outcome of ovarian cancer patients. The G allele has been implicated in the formation of active HER2 receptors, with a more aggressive phenotype. We hypothesize that HER2 genotypes can be predictive biomarkers in ovarian cancer, contributing to a genetic individual profile of great interest in clinical oncology.
Insights
Genetic variations in the HER2 gene impact ovarian cancer (OC) treatment outcomes. Patients with the valine homozygotic genotype showed lower survival, suggesting HER2 genotypes as potential predictive biomarkers for OC.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Chemotherapy resistance is a major challenge in ovarian cancer (OC) treatment.
- Genetic variations, particularly in the HER2 receptor, are linked to cancer development and progression.
- The HER2 receptor's role in ovarian cancer warrants further investigation regarding its genetic influence on patient outcomes.
Purpose of the Study:
- To investigate the association between a specific polymorphism in the HER2 gene and the clinical outcome of ovarian cancer patients.
- To determine if HER2 genotypes can serve as predictive biomarkers for ovarian cancer prognosis.
Main Methods:
- DNA samples from 111 ovarian cancer patients treated with cisplatin and paclitaxel were analyzed.
- Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP) was employed to characterize HER2 gene polymorphisms.
Main Results:
- Patients with the valine homozygotic genotype exhibited a significantly lower overall survival rate.
- The G allele of the HER2 polymorphism is associated with active HER2 receptors and a more aggressive cancer phenotype.
Conclusions:
- The studied HER2 polymorphism may play a role in ovarian cancer patient outcomes.
- HER2 genotypes show potential as predictive biomarkers for personalized treatment strategies in ovarian cancer.
- Establishing a genetic profile for ovarian cancer patients could enhance clinical oncology approaches.
